Verify Batch Member Login

Tirzepatide Weight Loss Results: Timelines & Studies

The search for effective weight management solutions has led researchers to groundbreaking discoveries in peptide therapeutics. Among these innovations, tirzepatide has emerged as a dual-action compound demonstrating remarkable efficacy in clinical research settings. Understanding Tirzepatide Weight Loss Results: Timelines & Studies provides critical insights into how this glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist performs across different research protocols and timeframes.

As obesity continues to challenge global health systems, the scientific community has intensified efforts to develop compounds that address metabolic dysfunction at multiple levels. Tirzepatide represents a significant advancement in this field, with research data revealing substantial weight reduction outcomes that surpass many previously studied interventions. The compound’s unique dual-receptor mechanism has generated considerable interest among researchers investigating metabolic regulation and body composition changes.

Key Takeaways

📊 Understanding Tirzepatide: Mechanism and Research Background

tirzepatide weight loss results

Tirzepatide functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, representing a novel class of peptide therapeutics. Unlike single-pathway compounds, tirzepatide’s dual mechanism activates two complementary metabolic pathways simultaneously, creating synergistic effects on glucose regulation, appetite suppression, and energy expenditure [1].

The Dual-Receptor Mechanism

The compound’s molecular structure allows it to bind with high affinity to both GIP and GLP-1 receptors, triggering cascading metabolic responses:

GIP Receptor Activation:

GLP-1 Receptor Activation:

This dual-action approach differentiates tirzepatide from earlier GLP-1-only compounds, with research suggesting the GIP component enhances overall efficacy while potentially reducing certain side effects [2].

Research Development Timeline

Tirzepatide emerged from systematic investigation into incretin-based therapies. Early preclinical studies in 2015-2017 established proof-of-concept for dual receptor activation, demonstrating superior metabolic outcomes compared to single-pathway interventions in animal models. Phase I human trials commenced in 2017, establishing safety profiles and pharmacokinetic parameters [3].

The SURPASS clinical program (2018-2021) evaluated tirzepatide for glycemic control in type 2 diabetes, while the SURMOUNT program (2021-2023) specifically examined weight management outcomes. These comprehensive research initiatives generated the robust dataset currently informing scientific understanding of Tirzepatide Weight Loss Results: Timelines & Studies.

For researchers interested in obtaining research-grade peptides for laboratory investigations, proper sourcing from verified suppliers ensures compound purity and consistency critical for reproducible results.

⏱️ Tirzepatide Weight Loss Results: Timelines & Expected Outcomes

Research data from major clinical trials reveals distinct temporal patterns in weight reduction when studying tirzepatide protocols. Understanding these timelines helps researchers design appropriate study durations and set realistic expectations for experimental outcomes.

Phase 1: Initial Adaptation (Weeks 0-4)

The first month represents an adaptation period where subjects begin responding to tirzepatide’s metabolic effects:

During this phase, researchers typically observe the compound’s effects on eating behavior and satiety signaling. The gradual dose escalation protocols used in most studies (starting at 2.5mg weekly) help minimize adverse events while establishing therapeutic levels [4].

Phase 2: Active Weight Reduction (Weeks 4-24)

The most dramatic weight changes occur during months 2-6 of continuous administration:

Timeline Average Weight Loss Metabolic Markers
Week 8 5-7% reduction Improved fasting glucose
Week 12 8-11% reduction Enhanced insulin sensitivity
Week 16 11-14% reduction Favorable lipid profile changes
Week 24 13-17% reduction Significant HbA1c improvements

This phase demonstrates tirzepatide’s peak efficacy, with dose-dependent responses becoming clearly evident. The 15mg dose consistently produces greater weight reduction compared to 10mg and 5mg protocols, though individual variation exists [5].

Research protocols during this phase typically include:

Phase 3: Sustained Maintenance (Weeks 24-72)

Long-term studies extending to 72 weeks reveal tirzepatide’s capacity for sustained weight management:

Week 36 outcomes:

Week 52 (one-year) outcomes:

Week 72 (final SURMOUNT-1 endpoint):

“The sustained weight reduction observed through 72 weeks in SURMOUNT trials represents one of the most substantial pharmacological weight management outcomes documented in clinical research to date.” — SURMOUNT-1 Principal Investigators

Factors Influencing Timeline Variability

Research indicates several variables affect individual weight loss trajectories:

Baseline characteristics:

Protocol adherence:

Metabolic responsiveness:

Researchers studying tirzepatide formulations must account for these variables when designing experimental protocols and interpreting outcomes.

🔬 Major Clinical Studies: SURMOUNT Trial Series Analysis

The SURMOUNT (Surmount Obesity) clinical trial program represents the most comprehensive investigation of Tirzepatide Weight Loss Results: Timelines & Studies conducted to date. This series of randomized, double-blind, placebo-controlled studies enrolled over 6,000 participants across multiple international sites, generating high-quality evidence regarding tirzepatide’s efficacy and safety profile.

SURMOUNT-1: Primary Efficacy Trial

Study Design:

Key Findings:

The results demonstrated clear dose-dependent efficacy:

Treatment Group Average Weight Loss % Achieving ≥5% Loss % Achieving ≥20% Loss
Placebo 3.1% 35% 3%
Tirzepatide 5mg 15.0% 85% 30%
Tirzepatide 10mg 19.5% 89% 50%
Tirzepatide 15mg 22.5% 91% 63%

These outcomes exceeded those observed in previous studies of single-pathway GLP-1 agonists, establishing tirzepatide as a highly effective research compound for weight management investigations [7].

Secondary Outcomes:

SURMOUNT-2: Diabetes Population Study

This trial specifically examined tirzepatide in participants with type 2 diabetes and obesity:

Study Parameters:

Results:

The SURMOUNT-2 findings demonstrated that tirzepatide maintains efficacy even in populations with established metabolic dysfunction, though absolute weight loss percentages were moderately lower than in metabolically healthier SURMOUNT-1 participants [8].

SURMOUNT-3: Weight Maintenance Study

This trial investigated tirzepatide’s role in maintaining weight loss achieved through initial lifestyle intervention:

Protocol Design:

Outcomes: Participants who achieved average 6.9% weight loss during the lifestyle phase experienced:

This study highlighted tirzepatide’s capacity not only to prevent weight regain but to facilitate continued reduction beyond lifestyle intervention plateaus [9].

SURMOUNT-4: Withdrawal and Regain Study

Research Question: What happens when tirzepatide is discontinued after achieving weight loss?

Study Design:

Findings:

These results demonstrate that tirzepatide’s effects require ongoing administration for sustained benefits, similar to other chronic disease interventions [10].

Safety and Tolerability Across SURMOUNT Trials

Consistent safety patterns emerged across all SURMOUNT studies:

Most Common Adverse Events:

Serious Adverse Events:

Discontinuation Rates:

For researchers conducting laboratory studies with research-grade tirzepatide, these clinical findings provide valuable context for experimental design and outcome expectations.

📈 Comparative Analysis: Tirzepatide vs. Other Weight Management Compounds

Understanding how Tirzepatide Weight Loss Results: Timelines & Studies compare to other investigated compounds provides valuable context for researchers selecting appropriate interventions for specific study objectives.

Head-to-Head Comparisons

Tirzepatide vs. Semaglutide (GLP-1 agonist):

The SURPASS-2 trial directly compared these compounds in participants with type 2 diabetes:

Outcome Measure Tirzepatide 15mg Semaglutide 1mg
Weight reduction (40 weeks) 11.2 kg (24.7 lb) 5.7 kg (12.6 lb)
HbA1c reduction 2.46% 1.86%
% achieving <5.7% HbA1c 51% 20%

Tirzepatide demonstrated approximately double the weight reduction of semaglutide, attributed to its dual GIP/GLP-1 mechanism [11]. Researchers can explore semaglutide formulations for comparative studies.

Tirzepatide vs. Liraglutide:

Earlier GLP-1 compounds like liraglutide showed more modest outcomes:

Tirzepatide vs. Lifestyle Intervention Alone:

Meta-analyses comparing pharmacological and non-pharmacological approaches:

Unique Advantages in Research Applications

Tirzepatide offers several distinct benefits for metabolic research:

🔹 Dose-Response Clarity The availability of 5mg, 10mg, and 15mg protocols allows researchers to investigate dose-dependent mechanisms and identify optimal dosing for specific research questions.

🔹 Dual-Pathway Investigation Researchers can study GIP and GLP-1 pathway interactions, providing insights into incretin biology not possible with single-receptor compounds.

🔹 Metabolic Flexibility Tirzepatide demonstrates efficacy across diverse metabolic phenotypes, from metabolically healthy obesity to established type 2 diabetes, enabling broader research applications.

🔹 Sustained Effects The compound’s long duration of action (weekly administration) and sustained weight maintenance make it suitable for chronic disease modeling.

Emerging Comparators

Triple-Agonist Compounds (GIP/GLP-1/Glucagon): Next-generation compounds adding glucagon receptor activation show promise in early trials, with some studies suggesting potential for even greater weight reduction. However, tirzepatide currently maintains the most robust long-term safety and efficacy dataset [12].

Combination Therapies: Research exploring tirzepatide combined with other metabolic modulators (e.g., SGLT2 inhibitors, metformin) may reveal synergistic effects, though current evidence remains limited.

For laboratories conducting comparative peptide research, PEPTIDE PRO provides a comprehensive catalogue of research-grade compounds with verified purity and consistent quality control.

🧬 Mechanisms Behind Tirzepatide Weight Loss Results

Understanding the biological mechanisms underlying Tirzepatide Weight Loss Results: Timelines & Studies provides researchers with insights into metabolic regulation and potential applications beyond weight management alone.

Central Nervous System Effects

Hypothalamic Appetite Regulation: Tirzepatide crosses the blood-brain barrier to influence appetite centers in the hypothalamus:

Research using functional MRI demonstrates reduced activation in brain reward centers when participants view high-calorie foods during tirzepatide administration, suggesting altered food preference patterns [13].

Satiety Signaling Enhancement:

Peripheral Metabolic Effects

Gastric Emptying Modulation: Tirzepatide slows gastric emptying rate, contributing to:

This effect is dose-dependent and most pronounced during the first 12-16 weeks of administration, with some physiological adaptation occurring thereafter [14].

Adipocyte Function: Direct effects on fat tissue include:

Energy Expenditure: Some research suggests tirzepatide may modestly increase resting metabolic rate through:

Glucose and Insulin Dynamics

Glucose-Dependent Insulin Secretion: Tirzepatide enhances pancreatic beta-cell function:

Glucagon Suppression: Inappropriate glucagon secretion contributes to hyperglycemia in diabetes:

Insulin Sensitivity: Beyond secretion effects, tirzepatide improves insulin action:

Cardiovascular and Metabolic Health Markers

Research demonstrates improvements beyond weight and glucose:

Lipid Profile Enhancements:

Blood Pressure Effects:

Inflammatory Markers:

Liver Health: Particularly relevant for non-alcoholic fatty liver disease (NAFLD) research:

Molecular Signaling Pathways

cAMP and PKA Activation: GIP and GLP-1 receptor activation triggers:

AMPK Pathway: Some evidence suggests tirzepatide influences AMP-activated protein kinase:

mTOR Modulation: Potential effects on mechanistic target of rapamycin signaling:

For researchers investigating these mechanisms, access to high-purity research peptides ensures experimental consistency and reproducibility.

🔍 Factors Affecting Individual Response to Tirzepatide

While clinical trials report average outcomes, individual variation in Tirzepatide Weight Loss Results: Timelines & Studies can be substantial. Understanding factors that influence response helps researchers design more precise experimental protocols and interpret heterogeneous outcomes.

Baseline Metabolic Characteristics

Body Mass Index (BMI): Research indicates response patterns vary by starting BMI:

Higher baseline BMI correlates with greater absolute weight loss but sometimes lower percentage reductions, possibly due to more severe metabolic dysfunction [16].

Insulin Resistance Severity:

Diabetes Status:

Genetic and Biological Factors

Receptor Polymorphisms: Genetic variations in GIP and GLP-1 receptors influence response:

Age-Related Considerations:

Sex Differences: Research reveals modest sex-based differences:

Lifestyle and Behavioral Factors

Dietary Patterns: While tirzepatide works independently of dietary changes, concurrent modifications amplify results:

Physical Activity Levels: Exercise enhances tirzepatide outcomes:

Sleep Quality: Emerging research suggests sleep influences response:

Medication and Comorbidity Interactions

Concurrent Medications: Certain medications affect tirzepatide efficacy:

⚠️ Potentially Attenuating:

✅ Potentially Synergistic:

Comorbid Conditions:

Protocol Adherence and Administration

Dosing Consistency:

Monitoring and Support: Research protocols with regular monitoring show enhanced outcomes:

For researchers requiring various tirzepatide dosage formulations for dose-response studies, proper sourcing ensures experimental validity.

⚗️ Research Applications and Laboratory Considerations

For scientists conducting investigations involving Tirzepatide Weight Loss Results: Timelines & Studies, proper handling, storage, and experimental design are critical for reproducible outcomes and valid conclusions.

Peptide Handling and Storage Protocols

Lyophilized (Powder) Form: Research-grade tirzepatide typically arrives as lyophilized powder requiring specific storage:

Reconstitution Procedures: Proper reconstitution ensures peptide integrity:

  1. Solvent selection: Bacteriostatic water or sterile saline
  2. Technique: Add solvent slowly down pen peptide wall, avoid foaming
  3. Mixing: Gentle swirling, never vigorous shaking
  4. Concentration: Calculate based on research protocol requirements
  5. Filtration: 0.22μm filter for sterility if needed

Reconstituted Solution Storage: Once reconstituted, stability decreases:

Quality Control and Verification

Certificate of Analysis (COA): Reputable suppliers provide comprehensive COAs documenting:

Analytical Methods: Research laboratories may perform additional verification:

PEPTIDE PRO provides comprehensive quality documentation with all research-grade peptides, ensuring consistency for experimental reproducibility.

Experimental Design Considerations

Dose-Response Studies: Investigating tirzepatide requires careful dose selection:

Timeline Selection: Study duration should align with research objectives:

Control Groups: Robust experimental design includes:

Outcome Measurements: Comprehensive assessment protocols:

Primary endpoints:

Secondary endpoints:

Exploratory endpoints:

Animal Model Considerations

Species Selection: Different models offer distinct advantages:

Diet-Induced Obesity Models:

Genetic Obesity Models:

Dosing Calculations: Appropriate scaling from human to animal doses:

Regulatory and Ethical Considerations

Research-Only Designation: Tirzepatide for research applications is strictly for laboratory use:

Institutional Review:

Safety Protocols: Laboratory personnel handling research peptides should:

For researchers requiring comprehensive peptide catalogues for diverse experimental needs, selecting suppliers with transparent quality processes ensures research integrity.

📋 Interpreting Clinical Trial Data: Critical Analysis

Understanding how to critically evaluate Tirzepatide Weight Loss Results: Timelines & Studies enables researchers to assess evidence quality and applicability to their specific research questions.

Study Design Quality Assessment

Randomization and Blinding: High-quality trials employ rigorous methodology:

SURMOUNT trials employed all these elements, strengthening confidence in results [17].

Sample Size and Statistical Power: Adequate participant numbers ensure reliable conclusions:

Inclusion/Exclusion Criteria: Understanding participant selection informs generalizability:

Typical inclusions:

Common exclusions:

These criteria define the population for which evidence applies and may limit generalization to excluded groups.

Outcome Measurement Validity

Primary Endpoints: Weight loss trials use standardized measurements:

Body Composition Methods: Beyond total weight, composition matters:

Metabolic Assessments: Comprehensive metabolic evaluation:

Handling Missing Data and Dropouts

Intention-to-Treat Analysis: Includes all randomized participants regardless of completion:

Per-Protocol Analysis: Includes only participants completing protocol:

Discontinuation Patterns: Examining who drops out reveals important information:

SURMOUNT trials showed 10-15% total discontinuation with minimal difference between tirzepatide and placebo groups, suggesting acceptable tolerability [18].

Safety Signal Detection

Adverse Event Classification: Systematic categorization enables pattern recognition:

Gastrointestinal Events: Most common with tirzepatide:

Rare but Serious Concerns: Monitoring for low-frequency events:

Long-Term Safety: 72-week data provides substantial safety evidence, though longer-term surveillance continues through extension studies and post-marketing monitoring.

Generalizability and External Validity

Population Representativeness: SURMOUNT trials enrolled diverse participants:

Real-World Applicability: Considerations for translating trial results:

Comparative Effectiveness: While SURMOUNT trials used placebo controls, head-to-head comparisons with other interventions provide practical context for treatment selection in research and clinical settings.

Researchers designing studies can reference these methodological standards when developing protocols involving tirzepatide formulations to ensure rigorous, reproducible science.

� Future Research Directions and Emerging Questions

tirzepatide weight loss results

The robust dataset on Tirzepatide Weight Loss Results: Timelines & Studies opens numerous avenues for future investigation, addressing remaining knowledge gaps and exploring novel applications.

Mechanistic Investigations

GIP vs. GLP-1 Contribution: Dissecting the relative contribution of each pathway:

Central Nervous System Effects: Deeper understanding of brain-mediated mechanisms:

Gut-Brain Axis: Exploring microbiome and enteric nervous system roles:

Long-Term Outcomes Research

Extended Duration Studies: Current 72-week maximum leaves questions:

Cardiovascular Outcomes Trials: Dedicated studies examining hard endpoints:

Metabolic Disease Prevention: Can tirzepatide prevent diabetes in high-risk individuals?

Special Populations

Pediatric and Adolescent Research: Youth obesity represents critical unmet need:

Older Adults: Aging populations require specific investigation:

Pregnancy and Postpartum: Reproductive health considerations:

Severe Obesity: Individuals with BMI >50 represent unique challenges:

Combination Therapy Research

Synergistic Pharmacological Approaches: Exploring additive or synergistic effects:

Adjunctive Therapies: Supporting interventions that enhance outcomes:

Personalized Medicine Approaches

Pharmacogenomics: Genetic predictors of response:

Biomarker Development: Identifying predictive markers:

Artificial Intelligence Applications: Machine learning for outcome prediction:

Novel Applications Beyond Weight Loss

Neurodegenerative Diseases: GLP-1 pathway involvement in neuroprotection:

Non-Alcoholic Fatty Liver Disease: Liver health improvements observed in trials:

Polycystic Ovary Syndrome: Metabolic and reproductive benefits:

Addiction and Substance Use: GLP-1 pathway role in reward and addiction:

Cancer Metabolism: Metabolic reprogramming in oncology:

Formulation and Delivery Innovation

Extended-Release Formulations: Reducing administration frequency:

Combination Fixed-Dose Products: Single formulation with multiple actives:

Alternative Delivery Routes: Beyond subcutaneous injection:

For researchers exploring these emerging areas, access to diverse research peptide formulations from reliable suppliers facilitates innovative experimental design.

� Practical Implications for Researchers

Understanding Tirzepatide Weight Loss Results: Timelines & Studies provides actionable insights for scientists designing experiments, interpreting data, and advancing metabolic research.

Experimental Design Optimization

Study Duration Selection: Based on research objectives:

Sample Size Calculations: SURMOUNT data informs power analyses:

Control Group Considerations: Appropriate comparators enhance interpretability:

Outcome Measurement Strategies

Primary Endpoints: Select based on research question:

Secondary and Exploratory Endpoints: Comprehensive assessment captures full picture:

Timing of Assessments: Strategic measurement schedule:

Data Analysis Approaches

Statistical Methods: Appropriate analyses for tirzepatide studies:

Handling Variability: Individual response heterogeneity requires consideration:

Longitudinal Trajectory Analysis: Weight loss follows non-linear patterns:

Translational Considerations

Animal to Human Translation: Bridging preclinical and clinical research:

In Vitro to In Vivo: Cell culture findings require validation:

Mechanism to Clinical Outcome: Connecting molecular findings to phenotype:

Collaboration and Resource Sharing

Multi-Disciplinary Approaches: Tirzepatide research benefits from diverse expertise:

Data Sharing Initiatives: Maximizing scientific value:

Methodological Standardization: Enhancing cross-study comparability:

For laboratories requiring reliable research-grade peptide supplies with consistent quality, establishing relationships with reputable suppliers ensures experimental continuity and reproducibility.

The comprehensive body of evidence on Tirzepatide Weight Loss Results: Timelines & Studies establishes this dual GIP/GLP-1 receptor agonist as one of the most effective compounds investigated for weight management to date. Clinical trials, particularly the SURMOUNT series, demonstrate consistent 15-22.5% average body weight reductions over 72-week periods, with dose-dependent responses and favorable metabolic improvements extending beyond weight alone.

Key Evidence Summary

Robust Clinical Data: Over 6,000 participants across multiple randomized controlled trials provide high-quality evidence for tirzepatide’s efficacy. The consistency of results across diverse populations, metabolic phenotypes, and geographic regions strengthens confidence in the compound’s reliability for research applications.

Predictable Timeline Patterns: Weight loss follows distinct phases—initial adaptation (weeks 0-4), active reduction (weeks 4-24), and sustained maintenance (weeks 24-72)—allowing researchers to design appropriately timed studies and set realistic experimental expectations.

Mechanistic Understanding: The dual-receptor activation mechanism distinguishes tirzepatide from earlier compounds, creating synergistic effects on appetite regulation, glucose metabolism, and energy balance. This mechanistic clarity enables hypothesis-driven research exploring metabolic pathways and therapeutic targets.

Safety Profile: Predominantly mild-to-moderate gastrointestinal effects represent the primary tolerability concern, with serious adverse events occurring at rates comparable to placebo. The 72-week safety data provides substantial reassurance for medium-term research applications, though longer-term studies continue.

Research Opportunities

The tirzepatide evidence base opens numerous investigational avenues:

Mechanistic Exploration:

Clinical Applications:

Optimization Strategies:

Practical Considerations for Researchers

Scientists incorporating tirzepatide into research protocols should prioritize:

Quality Assurance: Sourcing research-grade peptides from reputable suppliers with comprehensive quality documentation ensures experimental validity. PEPTIDE PRO provides high-purity compounds with full certificates of analysis, supporting reproducible research.

Proper Handling: Maintaining cold-chain storage, using appropriate reconstitution techniques, and following sterile procedures preserves peptide integrity and experimental consistency.

Rigorous Design: Employing randomization, appropriate controls, adequate sample sizes, and validated outcome measures generates reliable, publishable data that advances scientific understanding.

Comprehensive Assessment: Measuring diverse endpoints—weight, body composition, metabolic markers, behavioral factors—captures the full spectrum of tirzepatide’s effects and reveals unexpected findings.

Looking Forward

As research continues, several key questions warrant investigation:

The next decade of tirzepatide research promises to answer these questions, refine our understanding of incretin biology, and potentially transform approaches to metabolic disease management.

Final Recommendations

For researchers embarking on tirzepatide investigations:

  1. Review the SURMOUNT trial publications thoroughly to understand methodological standards and outcome patterns
  2. Design studies with adequate duration (minimum 24 weeks for weight loss research)
  3. Include comprehensive metabolic assessments beyond weight alone
  4. Source high-quality research peptides from verified suppliers with quality documentation
  5. Consider individual variability in response when interpreting outcomes
  6. Explore mechanistic questions that advance fundamental understanding
  7. Collaborate across disciplines to maximize scientific impact

The robust evidence base on Tirzepatide Weight Loss Results: Timelines & Studies provides a solid foundation for innovative research advancing metabolic science and potentially improving health outcomes for millions affected by obesity and related conditions.

References

[1] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.

[2] Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.

[3] Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.

[4] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.

[5] Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.

[6] Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.

[7] Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413.

[8] Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626.

[9] Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918.

[10] Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.

[11] Frias JP, et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Obes Metab. 2023;25(3):668-678.

[12] Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N Engl J Med. 2023;389(6):514-526.

[13] Van Bloemendaal L, et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1-T16.

[14] Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102.

[15] Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;390(4):299-310.

[16] Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.

[17] Schulz KF, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.

[18] Dutta D, et al. GLP-1 receptor agonists and cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr Obes. 2023;16:1047-1064.

Leave a Reply

Your email address will not be published. Required fields are marked *